PuraPharm Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Abraham Chan

İcra Kurulu Başkanı

HK$6.2m

Toplam tazminat

CEO maaş yüzdesi	65.3%
CEO görev süresi	12.9yrs
CEO sahipliği	33.4%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	9.4yrs

Son yönetim güncellemeleri

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

CEO Tazminat Analizi

Abraham Chan'un ücretlendirmesi PuraPharm'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-HK$87m
Mar 31 2024	n/a	n/a	-HK$97m
Dec 31 2023	HK$6m	HK$4m	-HK$106m
Sep 30 2023	n/a	n/a	-HK$112m
Jun 30 2023	n/a	n/a	-HK$118m
Mar 31 2023	n/a	n/a	-HK$119m
Dec 31 2022	HK$4m	HK$4m	-HK$120m
Sep 30 2022	n/a	n/a	-HK$147m
Jun 30 2022	n/a	n/a	-HK$174m
Mar 31 2022	n/a	n/a	-HK$148m
Dec 31 2021	HK$4m	HK$4m	-HK$122m
Sep 30 2021	n/a	n/a	-HK$45m
Jun 30 2021	n/a	n/a	HK$32m
Mar 31 2021	n/a	n/a	HK$32m
Dec 31 2020	HK$4m	HK$3m	HK$32m
Sep 30 2020	n/a	n/a	-HK$69m
Jun 30 2020	n/a	n/a	-HK$171m
Mar 31 2020	n/a	n/a	-HK$199m
Dec 31 2019	HK$3m	HK$1m	-HK$227m
Sep 30 2019	n/a	n/a	-HK$132m
Jun 30 2019	n/a	n/a	-HK$38m
Mar 31 2019	n/a	n/a	-HK$8m
Dec 31 2018	HK$2m	HK$1m	HK$21m
Sep 30 2018	n/a	n/a	HK$13m
Jun 30 2018	n/a	n/a	HK$6m
Mar 31 2018	n/a	n/a	HK$4m
Dec 31 2017	HK$4m	HK$4m	HK$2m

Tazminat ve Piyasa: Abraham 'nin toplam tazminatı ($USD 797.08K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 232.62K ).

Tazminat ve Kazançlar: Abraham şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Abraham Chan (63 yo)

12.9yrs

Görev süresi

HK$6,205,000

Tazminat

Mr. Yu Ling Chan, also known as Abraham, BASc C.Eng. MIStruct E. P.Eng., has been the Chief Executive Officer and Chairman of PuraPharm Corporation Limited. Mr. Chan has been a Director at PuraPharm Corpor...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Ling Chan	Founder	12.9yrs	HK$6.21m	33.42% HK$ 84.5m
Yee Wai Man	Executive Director	12.9yrs	HK$3.51m	0.044% HK$ 110.4k
Kwok Wah Ho	Independent Non-Executive Director	9.4yrs	HK$200.00k	0.0046% HK$ 11.5k
Bruce Robinson	Chairman of Scientific Advisory Committee	8.7yrs	Veri yok	Veri yok
Lap-Chee Tsui	Independent Non-Executive Director	9.4yrs	HK$200.00k	0.0046% HK$ 11.5k
Lim Kin Leung	Independent Non-Executive Director	9.4yrs	HK$200.00k	0.0046% HK$ 11.5k
Piu Chan	Member of Scientific Advisory Committee	no data	Veri yok	Veri yok
Rudolf Bauer	Member of Scientific Advisory Committee	no data	Veri yok	Veri yok
Song Ming Liang	Member of Scientific Advisory Committee	no data	Veri yok	Veri yok
Chi Ming Che	Member of Scientific Advisory Committee	2.8yrs	Veri yok	Veri yok
Kwok Keung Leung	Non-Executive Director	1.4yrs	HK$109.00k	Veri yok

9.4yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1498 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).

PuraPharm Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş